Clinical Trials Browser

Withdrawn × Carboplatin × Breast × Clear all

NCT06829199 2026-02-19

MK-5890-003

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04419181 2025-10-14

Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer

Phase 2 Withdrawn

HER2-positive Breast Cancer

NCT05474690 2024-02-26

A Study Comparing the Efficacy of TCbHP and ECHP-THP in the Neoadjuvant Treatment of HER2-positive Breast Cancer

Phase 3 Withdrawn

Pathologic Complete Response, Breast Neoplasms

NCT05238831 2024-01-23

SMMART Adaptive Clinical Treatment (ACT) Trial

Phase EARLY_PHASE1 Withdrawn

BreastGastrointestinalGenitourinaryGynecologicSarcoma

Breast Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma

NCT05809895 2023-07-24

AdvanTIG-211

Phase 2 Withdrawn

Triple Negative Breast Neoplasms

NCT05093387 2022-11-15

SGT-53, Carboplatin, and Pembrolizumab for the Treatment of Metastatic Triple Negative Inflammatory Breast Cancer

Phase 1 Withdrawn

Inflammatory Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03872505 2021-08-25

PANDoRA

Phase 2 Withdrawn

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT00006123 2018-05-16

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Trastuzumab in Treating Women With Metastatic Breast Cancer

Phase 1/2 Withdrawn

Breast Neoplasms

NCT03032614 2017-10-10

Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients

Phase 2 Withdrawn

BreastGynecologic

Breast Neoplasms, Ovarian Neoplasms

NCT00397501 2017-04-21

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Phase 1/2 Withdrawn

Brain Neoplasms, Breast Neoplasms, Central Nervous System Neoplasms, Drug-Related Side Effects and Adverse Reactions

NCT02102438 2016-08-31

Chemotherapy for Elderly Patients Diagnosed With Localized HER2 Positive Breast Cancer

Phase NA Withdrawn

Breast Neoplasms

NCT02396433 2015-08-25

Combination of Carboplatin, Eribulin Mesylate, and E7449 in BRCA-Related Cancers

Phase 1/2 Withdrawn

Breast Neoplasms